Browsing Tag
Acute myeloid leukemia
36 posts
Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML
Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology,…
Kurome Therapeutics advances with FDA-approved IND for KME-0584 in AML and HR MDS clinical trial
In a significant development for cancer research, Kurome Therapeutics Inc. has announced the U.S. Food and Drug Administration…
Hemogenyx Pharmaceuticals receives FDA nod for HEMO-CAR-T AML treatment study
Hemogenyx Pharmaceuticals plc, a London-based biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA)…
Invivoscribe, Complete Genomics to develop biomarker tests for oncology research
Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s…
Rigel Pharmaceuticals gets Rezlidhia FDA approval for AML
Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules…
Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals
Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with…
Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS
CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient…
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based…
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth…
BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome
BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program…